CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 90.53 thousand shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-05-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2019-05-29
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2014-03-31 was -274.63K shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2013-12-31 was 0.00 shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2013-03-31 was 0.00 shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2012-12-31 was 0.00 shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2018 was 90.53K shares, a 84.61% decline from fiscal 2017.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2017 was 588.34K shares, a 15.36% increase from fiscal 2016.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2016 was 510.00K shares.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2015 was -25.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2018-12-31 | 90.53K shares 10-K · filed 2019-05-29 | |||
| 2017-12-31 | 588.34K shares 10-K · filed 2018-03-19 | |||
| 2016-12-31 | 510.00K shares 10-K · filed 2017-03-16 | |||
| 2015-12-31 | -25.00K shares 10-K · filed 2016-03-15 | |||
| 2014-12-31 | -574.63K shares 10-K · filed 2016-03-15 | |||
| 2014-03-31 | -274.63K shares 10-Q · filed 2014-05-15 | -274.63K shares derived: sum of 2 quarters · filed 2015-03-12 | ||
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-12 | -118.67K shares 10-K · filed 2015-03-12 | ||
| 2013-09-30 | -118.67K shares 10-Q/A · filed 2014-03-04 | |||
| 2013-03-31 | 0.00 shares 10-Q · filed 2014-05-15 | 0.00 shares derived: sum of 2 quarters · filed 2014-05-15 | ||
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2014-03-31 | -217.66K shares 10-K · filed 2014-03-31 | ||
| 2012-09-30 | -217.66K shares 10-Q/A · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |